Sheila Gujrathi - 20 Oct 2021 Form 3 Insider Report for Ventyx Biosciences, Inc. (VTYX)

Role
Director
Signature
/s/ Christopher Krueger, as Attorney-in-Fact
Issuer symbol
VTYX
Transactions as of
20 Oct 2021
Net transactions value
$0
Form type
3
Filing time
20 Oct 2021, 18:53:00 UTC
Previous filing
10 Jun 2021
Next filing
25 Oct 2021
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding VTYX Series A Preferred Stock 20 Oct 2021 Common Stock 32,897 Direct F1
holding VTYX Stock Option (right to buy) 20 Oct 2021 Common Stock 762,369 $6.03 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 All shares of the preferred stock, par value $0.0001 per share, of the Issuer will automatically be converted on a one-for-one basis to shares of the Issuer's common stock, par value $0.0001 per share ("Common Stock") prior to the closing of the Issuer's initial public offering of its Common Stock.
F2 Option granted under pursuant to the Issuer's 2019 Equity Incentive Plan, as amended (the "2019 Plan"). Subject to the Reporting Person continuing to be a Service Provider (as defined 2019 Plan) through each applicable date, one twenty-fourth (1/24th) of the shares subject to the option shall vest each month following the Vesting Commencement Date on the same day of the month as the Vesting Commencement Date (and if there is no corresponding day, on the last day of the month). "Vesting Commencement Date" shall mean May 14, 2021.

Remarks:

Exhibit 24 - Power of Attorney